NasdaqGS · Biotechnology

Aardvark Therapeutics (AARD)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+112.6%

$14.50 average target

$6.82+0.93 (+15.8%)Latest market snapshot · Yahoo Finance

Market cap$149.3M

Cash$73.9M

Quarterly burn$18.9M

Pipeline assets2

Short float4.5%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 112.6% upsideTargets are estimates—not guarantees—and can change after company updates.

$14.50Average target

Wall Street consensus

BuyBased on 10 analyst opinions

12ratings

Buy 6Hold 4Sell 2

Price-target range

$14.50

+112.6%

Low $3.00High $45.00

CurrentAverage

Bear case$3.00-56.0%

Base case$14.50+112.6%

Bull case$45.00+559.8%

Analyst coverage10published opinions

Bullish share50%buy recommendations

Target spread$42low-to-high dispersion

Consensus score2.31.0 is strongest

Recommendation mix

Current rating breakdown

12 tracked ratings

Company profile

About Aardvark Therapeutics

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.